Tango Therapeutics, Inc.

Report azionario NasdaqGM:TNGX

Capitalizzazione di mercato: US$3.0b

Tango Therapeutics Gestione

Criteri Gestione verificati 2/4

Tango Therapeutics Il CEO è Malte Peters, nominato in Jan2026, ha un mandato di meno di un anno. possiede direttamente 0.008% delle azioni della società, per un valore di $ 237.23K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.3 anni e 5.3 anni.

Informazioni chiave

Malte Peters

Amministratore delegato

US$1.2m

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEOless than a year
Proprietà del CEO0.008%
Durata media del managementless than a year
Durata media del Consiglio di amministrazione5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • May 17

Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat

Summary Tango Therapeutics is downgraded from "Buy" to "Hold" due to a major, unproven strategy shift for vopimetostat. The company now prioritizes combination trials of vopimetostat with RAS[ON] inhibitors for 1st-line MTAP-del pancreatic cancer, with pivotal trial design pending new data. Upcoming catalysts include phase 1/2 data for vopimetostat in lung cancer and TNG456 in glioblastoma, but outcomes remain uncertain. With $379.8M cash on hand, the company has enough to fund its operations through 2028. Read the full article on Seeking Alpha
Articolo di analisi • Jan 19

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders have had their patience rewarded with a 53% share price jump in...
Articolo di analisi • Dec 05

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32%

Despite an already strong run, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have been powering on, with a gain of...
Articolo di analisi • Sep 17

Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected

With a price-to-sales (or "P/S") ratio of 33.7x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be sending very bearish...
Articolo di analisi • May 15

US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results

The analysts might have been a bit too bullish on Tango Therapeutics, Inc. ( NASDAQ:TNGX ), given that the company fell...
Articolo di analisi • Apr 14

Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 28% in the last...
Articolo di analisi • Apr 04

Here's Why We're Watching Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
Articolo di analisi • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Not Doing Enough For Some Investors As Its Shares Slump 30%

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
Seeking Alpha • Jan 23

Tango Therapeutics: Chance For A Short Squeeze

Summary Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative sentiment, recent institutional selling and call option activity suggest potential value accumulation and positive momentum for TNGX. I decided to buy OTM call options on TNGX due to the low implied volatility. Read the full article on Seeking Alpha
Articolo di analisi • Dec 05

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Oct 31

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 26% in the last...
Seeking Alpha • Sep 10

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Summary Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts. Despite the high risk, Tango's differentiated approach and potential blockbuster candidates make TNGX stock an intriguing speculative buy ahead of critical data readouts. Read the full article on Seeking Alpha
Articolo di analisi • Sep 01

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have continued their recent momentum with a 29% gain in the last month...
Articolo di analisi • Jun 29

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a really impressive month, gaining 27% after a shaky period...
Articolo di analisi • May 30

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Key Insights Tango Therapeutics will host its Annual General Meeting on 5th of June Salary of US$626.0k is part of CEO...
Articolo di analisi • Mar 19

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a horrible month, losing 30% after a relatively good period...
Articolo di analisi • Mar 06

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tango Therapeutics...
Articolo di analisi • Jan 08

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

You may think that with a price-to-sales (or "P/S") ratio of 25x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) is a stock to...
Articolo di analisi • Nov 09

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Shareholders in Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be thrilled to learn that the analysts have just delivered...
Articolo di analisi • Aug 12

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders will have a reason to smile today, with the analysts making...
Articolo di analisi • May 10

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Oct 20

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

H.C. Wainwright has started Tango Therapeutics (NASDAQ:TNGX) with a buy rating citing its use of synthetic lethality to develop cancer candidates. The firm has a $10 price target (~43% upside based on Wednesday's close). Analyst Robert Burns said that the targets the company is focused on could potentially treat large patient populations. He cited TNG908, Tango's (TNGX) most advanced candidate, currently in phase 1/2 for MTAP-deleted tumors. Initial data is expected in H1 2023. After determining the optimum dose for TNG908, Tango (TNGX) says it will evaluate efficacy in multiple tumor types in specific cohorts, including malignant peripheral nerve sheath tumor, non-small cell lung cancer, mesothelioma, cholangiocarcinoma, and glioblastoma. Seeking Alpha's Quant Rating views Tango (TNGX) as a buy with high marks for growth and momentum.
Articolo di analisi • Oct 05

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Articolo di analisi • Aug 13

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

The investors in Tango Therapeutics, Inc. 's ( NASDAQ:TNGX ) will be rubbing their hands together with glee today...
Seeking Alpha • Aug 10

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Tango Therapeutics press release (NASDAQ:TNGX): Q2 GAAP EPS of -$0.28 beats by $0.03. Revenue of $5.78M (-68.2% Y/Y) beats by $0.12M.
Articolo di analisi • May 28

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Jan 06

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

AMMINISTRATORE DELEGATO

Malte Peters (63 yo)

less than a year
Mandato
US$1,151,381
Compensazione

Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Barbara Weber
Founder & Executive Chair9.2yrsUS$2.82m1.07%
$ 32.7m
Malte Peters
Presidentless than a yearUS$1.15m0.0078%
$ 237.2k
Adam Crystal
President of Research & Development3.3yrsUS$1.72m0.078%
$ 2.4m
Alan Ashworth
Founder & Member of Scientific Advisory Boardno dataNessun datoNessun dato
William Kaelin
Founder & Member of Scientific Advisory Boardno dataNessun datoNessun dato
Antoni Ribas
Founder & Member of Scientific Advisory Boardno dataNessun datoNessun dato
Matthew Gall
Chief Financial Officerless than a yearNessun datoNessun dato
Jannik Andersen
Chief Scientific Officer2.6yrsNessun datoNessun dato
Julie Fogarty
Vice President of Legal & Corporate Secretaryno dataNessun datoNessun dato
Julie Carretero
Chief Human Resources Officer2.2yrsNessun datoNessun dato
Philippe Serrano
Chief Regulatory Officerless than a yearNessun datoNessun dato
Janice Kapty
Senior Vice President of Corporate Strategy & Project Leadershipless than a yearNessun datoNessun dato
0.3yrs
Durata media
60.5yo
Età media

Gestione esperta: Il team dirigenziale di TNGX non è considerato esperto (durata media 0.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Barbara Weber
Founder & Executive Chair9.2yrsUS$2.82m1.07%
$ 32.7m
Malte Peters
President7.7yrsUS$1.15m0.0078%
$ 237.2k
Alan Ashworth
Founder & Member of Scientific Advisory Board5.3yrsNessun datoNessun dato
William Kaelin
Founder & Member of Scientific Advisory Board5.3yrsNessun datoNessun dato
Antoni Ribas
Founder & Member of Scientific Advisory Board5.3yrsNessun datoNessun dato
Mace Rothenberg
Independent Director5.2yrsUS$169.70k0.0078%
$ 237.2k
Lesley Calhoun
Independent Director5.2yrsUS$176.33k0.0043%
$ 131.7k
John Ketchum
Independent Director2.8yrsUS$196.14k0.0078%
$ 239.4k
Sung Lee
Lead Independent Directorless than a yearNessun dato0%
$ 0
Alan Huang
Member of Scientific Advisory Board1.3yrsUS$1.88mNessun dato
5.3yrs
Durata media
63.5yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TNGX sono considerati esperti (durata media dell'incarico 5.3 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/21 10:19
Prezzo dell'azione a fine giornata2026/05/21 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Tango Therapeutics, Inc. è coperta da 14 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Yuan ZhiB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Eric SchmidtCantor Fitzgerald & Co.